New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1
Interim analysis demonstrated long-term safety and suggested a sustained effect of nintedanib on slowing lung function decline in patients with SSc-ILD1
Safety and efficacy profile of nintedanib was consistent with the Phase III SENSCIS® trial, according to this analysis1
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced results from an interim analysis of the SENSCIS®-ON trial evaluating nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The new analysis was published online as part of ACR Convergence 2020.
SENSCIS-ON is an open-label extension trial to assess the long-term safety of nintedanib in patients with SSc-ILD who completed the Phase III SENSCIS® trial. The study is evaluating the absolute and relative change from baseline in the forced vital capacity (FVC) as a measure of lung function over 52 weeks.1,2
The interim analysis showed that the safety profile of nintedanib in SENSCIS-ON was consistent with that reported over 52 weeks in the SENSCIS trial with diarrhea being the most frequently reported adverse event.1 The analysis showed that 347 patients in the extension study who received nintedanib demonstrated a decrease in FVC over 52 weeks as did patients in the SENSCIS study.1 The average change in FVC from baseline to week 52 of SENSCIS-ON was −51.3 mL in all patients treated in SENSCIS-ON, while the change from baseline to week 52 in the SENSCIS trial was −42.7 mL.1
“Boehringer Ingelheim is continuously committed to providing scientific data, offering clinicians more confidence in treating patients with SSc-ILD,” commented Dr. Susanne Stowasser, Associate Medical Head Pulmonology at Boehringer Ingelheim. “We are thrilled to share the new data demonstrating a similar consistent safety profile of nintedanib in people living with SSc-ILD and suggesting a sustained effect in slowing lung function decline.”
~Ends~
新时期、新中考 --广外伴你开启新梦想--
达因苏边境派出所学习贯彻党的十九届五中全会
从24岁开始学ABC 邓亚萍《我相信》亲述求学之路
铠侠将向乌克兰人民捐赠1亿日元,用于人道主
调查组:权健部分产品涉虚假宣传 已请专家协助
WGS 2019:世界政府峰会无疑是全球重要改变的催
吉利汽车获莱茵整车级固体颗粒物气溶胶过滤防
韩国自动化专业企业KCC精工瞄准海外市场
湖北建华建设工程咨询有限公司为新冠战“疫”
Bentley 软件公司宣布基础设施项目利用由
Court Denies Majority of Moto
APR获得1万亿韩元的Pre-IPO投资
固铂轮胎赢得两项2019 GOOD DESIGN®全球大奖
湘潭市开展健康促进医院创建考评验收工作
嘉盛电源获颁TuV莱茵国内首张DIN 70122
教育现代化浪潮下 “游戏化”教育加速入场
新的独立研究报告显示,数据虚拟化可带来40
MSCI推出第一批数字资产指数
2020ITES深圳工业展完美收官,百超迪能重磅亮相
鼎和保险公司多措并举应对沙尘暴天气
akaBot携手Soroco提升流程优化解决方案
Takeda to Divest TachoSil
滨城区四中线上升旗仪式——传承五四精神,绽
Forescout拓展亚太和日本业务,新设新加坡总部